Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial-Reference-Cited by-同舟云学术

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Published:2022-06 Issue:6 Volume:28 Page:1178-1188
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Reijers Irene L. M.,Menzies Alexander M.,van Akkooi Alexander C. J.,Versluis Judith M.,van den Heuvel Noëlle M. J.,Saw Robyn P. M.^ORCID,Pennington Thomas E.,Kapiteijn Ellen,van der Veldt Astrid A. M.,Suijkerbuijk Karijn P. M.,Hospers Geke A. P.^ORCID,Rozeman Elisa A.,Klop Willem M. C.,van Houdt Winan J.,Sikorska Karolina,van der Hage Jos A.^ORCID,Grünhagen Dirk J.^ORCID,Wouters Michel W.^ORCID,Witkamp Arjen J.,Zuur Charlotte L.,Lijnsvelt Judith M.,Torres Acosta Alejandro,Grijpink-Ongering Lindsay G.,Gonzalez Maria,Jóźwiak Katarzyna,Bierman Carolien,Shannon Kerwin F.^ORCID,Ch’ng Sydney,Colebatch Andrew J.,Spillane Andrew J.^ORCID,Haanen John B. A. G.^ORCID,Rawson Robert V.,van de Wiel Bart A.,van de Poll-Franse Lonneke V.,Scolyer Richard A.^ORCID,Boekhout Annelies H.,Long Georgina V.^ORCID,Blank Christian U.^ORCID

Funder

Bristol-Myers Squibb

Financial support for the study was provided by Bristol-Meyers Squibb

Department of Health | National Health and Medical Research Council

Melanoma Institute Australia and Nicolas and Helen More

Melanoma institute Australia

Clinical research Scholarship from Sydney Research

NHMRC program grant and practitioner fellowship

University of Sydney | Sydney Medical School | Sydney Medical School Foundation

NHMRC investigator grant

Publisher

Springer Science and Business Media LLC